Latest period
−$8.73M
YoY change
-40.4%
5Y CAGR
—
Peak year (2018)
−$8.57M
Latest annual
−$33.33M
Operating Cash Flow history chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: −$33.33M
Operating Cash Flow growth chart for Spruce Biosciences (SPRB) from 2018 to 2025
Latest: -40.4%
Operating Cash Flow history table for Spruce Biosciences (SPRB) from 2018 to 2025
| 2025 | −$33.33M | -40.4% | +$22.64M | ||
| 2024 | −$55.96M | +68.2% | −$22.69M | ||
| 2023 | −$33.27M | -20.2% | +$8.41M | ||
| 2022 | −$41.68M | +16.2% | −$5.81M | ||
| 2021 | −$35.88M | +30.4% | −$8.36M | ||
| 2020 | −$27.52M | +118.1% | −$14.90M | ||
| 2019 | −$12.62M | +47.2% | −$4.05M | ||
| 2018 | −$8.57M | — | — |
- 2025−$33.33M-40.4%
- 2024−$55.96M+68.2%
- 2023−$33.27M-20.2%
- 2022−$41.68M+16.2%
- 2021−$35.88M+30.4%
- 2020−$27.52M+118.1%
- 2019−$12.62M+47.2%
- 2018−$8.57M—
Operating Cash Flow values are taken from Spruce Biosciences's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Spruce Biosciences (SPRB)
Operating Cash Flow for Spruce Biosciences (SPRB): headline value −$8.73M · YoY -40.4%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Spruce Biosciences (SPRB) operating cash flow is −$33.33M – plunged 40.4% year-over-year.
The highest annual operating cash flow of −$8.57M was reported in 2018. The lowest in the available history was −$55.96M in 2024.
Spruce Biosciences Operating Cash Flow by Year
Spruce Biosciences Operating Cash Flow 2025: −$33.33M
Spruce Biosciences operating cash flow in 2025 was −$33.33M, plunged 40.4% below 2024.
Spruce Biosciences Operating Cash Flow 2024: −$55.96M
2024's operating cash flow for Spruce Biosciences came in at −$55.96M, surged 68.2% from 2023. This figure represents the lowest annual value in the available history.
Spruce Biosciences Operating Cash Flow 2023: −$33.27M
Spruce Biosciences posted operating cash flow of −$33.27M in 2023, declined 20.2% below 2022.
Spruce Biosciences Operating Cash Flow 2022: −$41.68M
In 2022, Spruce Biosciences reported operating cash flow of −$41.68M, grew 16.2% from 2021.
Spruce Biosciences Operating Cash Flow 2021: −$35.88M
Spruce Biosciences operating cash flow in 2021 was −$35.88M.
See more financial history for Spruce Biosciences (SPRB).
Sector peers by Operating Cash Flow
Healthcare peers of Spruce Biosciences (SPRB), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Spruce Biosciences (SPRB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation